期刊文献+

分泌AFP的人肝癌细胞株中阳离子脂质体介导肝癌组织特异性载体的表达 被引量:2

Expression of tissue-specific vector mediated by cationic liposome in α-fetoprotein-positive human hepatocarcinoma cell line
下载PDF
导出
摘要 目的 :研究阳离子脂质体 (cationicliposome)介导甲胎蛋白 (α fetoprotein ,AFP)启动子 /增强子载体在分泌AFP的人肝癌细胞株中的靶向表达。方法 :测定比较阳离子脂质体Lipofectin介导质粒pDR2 luc、pEBAFluc转染分泌AFP的人肝癌细胞株 (HepG2 )、不分泌AFP的人肝癌细胞株 (SMMC772 1 )、人肾癌细胞株 (GRC)及非洲绿猴肾细胞(COS7)的转染效率 ,通过液体闪烁计数仪单光子计数法测定荧光素酶活性 ,估计转染效率。结果 :①以Lipofectin介导pDR2 luc转染 4株细胞 ,荧光素酶活性在 4株细胞中均能表达 ,且表达活性差异有统计学意义 (P <0 .0 5 ) ;②以Lipofectin介导pEBAFluc转染 4株细胞 ,荧光素酶活性仅在能分泌AFP的HepG2 中表达。结论 :含人AFP启动子 Aim: To study the targeting effect to the α fetoprotein(AFP) positive human hepatocarcinoma cell line by the cationic liposome mediated by transfection of tissue specific vector. Methods: Plasmid pDR 2luc and pEBAFluc contained the firefly luciferase reporter gene under the control of the RSV LTR promoter and the AFP promoter, respectively. Four cell lines including human hepatocarcinoma cell line HepG 2and SMMC7721, human renal carcinoma cell line GRCand simian kidney cell line COS 7were used to be transfected by cationic liposome Lipofectin. The transfection efficiency was evaluated by the activity of expressed luciferase. Results: When transfected with lipofectin pDR 2luc, the Luciferase activity expressed in four cell lines and were statistically significant ( P < 0.05). When transfected with Lipofectin pEBAFluc, the luciferase activity only expressed in HepG 2, but did not expressed in the other three cell lines. Conclusion: pEBAFluc vector harboring AFP promoter/enhancer has targeting effect to the AFP positive hepatocarcinoma cells.
出处 《郑州大学学报(医学版)》 CAS 北大核心 2004年第4期613-616,共4页 Journal of Zhengzhou University(Medical Sciences)
关键词 脂质体 甲胎蛋白 转录调控序列 肝细胞 liposome α fetoprotein transcriptional regulatory sequences carcinoma, hepatocellular
  • 相关文献

参考文献13

  • 1姚琳莉.高职院校企业化校园文化建设途径探讨[J].职业教育研究,2010(1):24-25. 被引量:5
  • 2Luehrsen KR,de Wet JR,Walbot V. Transient expression analysis in plants using firefly luciferase reporter gene. Methods Enzymol,1992,216:397
  • 3Norman JA, Parker S, Lew D, et al. Preclinincal pharmacyokinetics, manufacturing, and safety studies supporting a multicenter cancer gene therapy trial. Hum Gene Ther,1995,6(5):549
  • 4Smith KT, Shepherd AJ, Boyd JE, et al. Gene delivery systems for use in gene therapy: an review of quality assuance and safety issues. Gene Ther,1996,3(3):190
  • 5Nabel GJ,Nabel EG,Yang ZY,et al.Direct gene transfer with DNA-liposome complexes in melanoma:expression,biologic activity and lack of toxicity in human.Proc Natl Acad Sci USA,1993,90(23):11 307
  • 6Watanable K, Saito A, Tamaoki T. Cell specific enhancer activity in a far upstream region of the human α-fetoprotein gene. J Biol Chem,1987,262(10):4 812
  • 7Ido A, Nakata K, Kato Y, et al. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of humanα-fetoprotein gene promoter. Cancer Res,1995,55(14):3 105
  • 8Huber BE, Richards CA, Krenitsky TA. Retrovirus-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy, Proc Natl Acad Sci USA,1991,88(18):8 039
  • 9Hirano T,Kaneko S,Kaneda Y,et al. HVJ-liposome-mediated transfection of HSVtk gene-driven by AFP promoter inhibits hepatic tumor growth of hepatocellular carcinomai in SCID mice. Gene Ther,2001,8(1):80
  • 10林菊生 李绍生.肝脏恶性肿瘤[A].见:梁扩寰主编.肝脏病学[C].北京:人民卫生出版社,1995.774-786.

二级参考文献16

共引文献14

同被引文献46

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部